Selvita to Acquire Fidelta from Galapagos for ~$37M

 Selvita to Acquire Fidelta from Galapagos for ~$37M

Selvita to Acquire Fidelta from Galapagos for ~$37M

Shots:

  • Selvita to acquire 100% of the outstanding shares in Fidelta for $37.08M + customary adjustments for net cash & working capital
  • The acquisition will expand Selvita’s integrated drug discovery services offering with the addition of Fidelta
  • Fidelta will be fully consolidated under Selvita Group & will continue to operate under the Fidelta name. Fidelta will continue to perform drug discovery services for Galapagos for the next five years

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Fidelta

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post